Friday, 22 October 2021

 

 

LATEST NEWS Make All Efforts For Instilling Confidence Of General Public In Law And Order Machinery- Cm To Punjab Police Youth To Be Deciding Factor In Vidhan Sabha Polls : Charanjit Singh Channi Massive protest against Cong MLA Joginderpal at Pathankot Police Commemoration Day observed at DPL Pulwama Intense Dengue control measures afoot Punjab Government To Come Up With A Roadmap To Revamp Education System : Pargat Singh The public knows who did corruption and who went to the court for the same : Vinod Thakur Central University of Punjab organized an Invited lecture on “Universal Human Values” Raja Warring's report card does not include any action against political transport mafia : Dinesh Chadha Tamannah Bhatia among top 10 most influential social media stars in south Being Punjabi an advantage in portraying a 'Sardar' : Pawan Malhotra Debina Bonnerjee's prosthetics for 'Shubho Bijoya' will leave you in shock Government recognizes Purzgars as vital pillar in Shawl Industry Police Martyrs Day observed at DPL Ganderbal, Pulwama Director Agriculture Kashmir inaugurates sale of Vegetable seedlings at Kitchen Garden, Lal Mandi Snow forecast : DC Bandipora reviews winter preparedness Disst. Adm. Kupwara organizes 4 block diwas programmes at Hayhama, Langate, Kalaroos, Tad Sonamarg to be promoted as all season tourist destination : Pandurang Kondbara Pole Charanjit Singh Channi Reviews Preparedness For Progressive Punjab Investors Summit We Should Fight Anti-National Forces Jointly : Gurpreet Singh Bhullar Commissionerate Police Give Rousing Welcome To Motorcycle Rally On Its Arrival At Jalandhar To Mark National Unity Day

 

Anti-diabetic drug can be re-purposed as Covid treatment: Study

Delta Plus Covid variant, Delta Covid-19 variant, Health, Study, Coronavirus, Research, Researchers, COVID 19, Novel Coronavirus, Fight Against Corona, Covaxin, Covishield,  Oxygen, Oxygen Cylinders, SARS-CoV-2, Sputnik V, Oxygen Plants, Pfizer, Astra Zeneca, Oxygen Concentrator, Remdesivir, Oxygen supply, Liquid Medical Oxygen, Oximeter

Web Admin

Web Admin

5 Dariya News

Hyderabad , 01 Jul 2021

Amid the rush to develop cures for the coronavirus, a study by a University of Hyderabad (UoH) incubated startup, has discovered that an anti-diabetic drug has potential use as a ready to use, cost-effective solution for safely treating Covid patients.In-vitro and in-silico studies conducted by ReaGene Innovations Private Limited, a startup company incubated at the ASPIRE-BioNEST, and INDRAS Private Limited, indicate that re-purposing the anti-diabetic drug Ertugliflozin, might provide a therapeutic solution to the Covid-19 infection.Ertugliflozin, an FDA approved drug for type-2 diabetes, works as SGLT-2 inhibitor by removing excessive glucose through urine.The research findings indicate that this re-purposed drug not only binds effectively to the receptor binding domain of the spike protein of Covid-19 and further blocks binding to human ACE2 but also displays significant anti-inflammatory and anti-thrombotic properties in a 3D human vascular lung model, both of which are fundamentals in Covid infection.This is the first result that offers a safe, ready-to-use, cost-effective solution to humans who contract Covid."It has immense potential to treat Covid infection, and our research proves its efficacy in the test-tube assays", said Dr Uday Saxena, CEO of ReaGene Innovations, co-founded with Dr Subramanyam Vangala, and Dr Sreedhara Voleti, MD of INDRAS.

INDRAS focus is on consulting, contracting, and collaborative solutions to in-silico drug design, has prioritized about 8,000 FDA approved drugs to top-10 from their computational studies, which were further experimented by ReaGene Innovations for various in-vitro assays on cytokine storm, antithrombotic properties, and inflammatory marker reduction through various in vitro assays.The path to find such a re-purposed drug was critically planned and completed within a year of funding from the IT giant, Tech Mahindra.The outcomes of the results of this research were recently published in a journal (BioRxIV) and a joint patent has been filed both in India as well as internationally under Patent Cooperation Treaty.The results obtained are highly encouraging, and further in animal models towards preclinical, and clinical outcomes in humans are yet to be conducted for this drug to be officially nominated as a therapeutic agent for COVID-19, the company said in a statement.ASPIRE-BioNEST is a life sciences incubator jointly funded by BIRAC, a section-8 not-for-profit organization of Department of Biotechnology, Govt of India, and University of Hyderabad (UoH) for nurturing scaling technologies through entrepreneurship.

 

Tags: Delta Plus Covid variant , Delta Covid-19 variant , Health , Study , Coronavirus , Research , Researchers , COVID 19 , Novel Coronavirus , Fight Against Corona , Covaxin , Covishield , Oxygen , Oxygen Cylinders , SARS-CoV-2 , Sputnik V , Oxygen Plants , Pfizer , Astra Zeneca , Oxygen Concentrator , Remdesivir , Oxygen supply , Liquid Medical Oxygen , Oximeter

 

 

related news

 

 

 

Photo Gallery

 

 

Video Gallery

 

 

5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2021 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD